Point-of-care diagnosis of tuberculosis: Past, present and future

Respirology

Volumn 18, Issue 2, 2013, Pages 217-232

  Dheda, Keertan ^a,b   Ruhwald, Morten ^c   Theron, Grant ^a   Peter, Jonathan ^a   Yam, Wing Cheong ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Mental Health Services CPH   (Denmark)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

antigen detection; diagnosis; NAAT; point of care; tuberculosis

Indexed keywords

APTAMER; BCG VACCINE; GAMMA INTERFERON; RIFAMPICIN; VOLATILE ORGANIC COMPOUND;

ANTIBODY DETECTION; ANTIGEN DETECTION; BACTERIAL LOAD; BACTERIAL OVERGROWTH; BACTERIUM DETECTION; BCG VACCINATION; BREATH ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYTOKINE RELEASE; DETERMINE TB LIPOARABINOMANNAN ANTIGEN TEST; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ELECTROCHEMISTRY; ELISA KIT; FOLLOW UP; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LAB ON A CHIP; LATENT TUBERCULOSIS; META ANALYSIS (TOPIC); MICROFLUIDICS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION; PHASE 3 CLINICAL TRIAL (TOPIC); POINT OF CARE TESTING; PREVALENCE; PRIORITY JOURNAL; RAMAN SPECTROMETRY; REVIEW; SENSITIVITY AND SPECIFICITY; SMEAR MICROSCOPY; SPUTUM EXAMINATION; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; XPERT MTB RIF ASSAY;

ELECTROCHEMICAL TECHNIQUES; HUMANS; IMMUNOLOGIC TESTS; MASS SPECTROMETRY; MICROFLUIDIC ANALYTICAL TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POINT-OF-CARE SYSTEMS; SPECTRUM ANALYSIS, RAMAN; TUBERCULOSIS, PULMONARY;

EID: 84872907783     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12022     Document Type: Review

References (128)

1. World Health Organization. The new WHO report on anti-tuberculosis drug resistance: multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. 2011; WHO/HTM/TB/2010.3.
2. Batz HG, Cooke GS,. Towards Lab-Free Tuberculosis Diagnosis. Treatment Action Group, Stop TB Partnership, Imperial College London and Me'decins Sans Frontie'res, New York, 2011.
3. Millen SJ, Uys PW, Hargrove J, et al. The effect of diagnostic delays on the drop-out rate and the total delay to diagnosis of tuberculosis. PLoS ONE 2008; 3: e1933.
4. Dheda K, Migliori GB,. The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? Lancet 2012; 379: 773-775.
5. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: A retrospective cohort study. Lancet 2010; 375: 1798-1807.
6. Dheda K, Warren RM, Zumla A, et al. Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect. Dis. Clin. North Am. 2010; 24: 705-725.
7. McNerney R, Daley P,. Towards a point-of-care test for active tuberculosis: obstacles and opportunities. Nat. Rev. Microbiol. 2011; 9: 204-213.
8. Pai NP, Pai M,. Point-of-care diagnostics for HIV and tuberculosis: landscape, pipeline, and unmet needs. Discov. Med. 2012; 13: 35-45.
9. Harries AD,. Tuberculosis and human immunodeficiency virus infection in developing countries. Lancet 1990; 335: 387-390. (Pubitemid 20059358)
10. Peter JG, Theron G, Muchinga TE, et al. The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce. PLoS ONE 2012; 7: e39966.
11. Peter JG, Theron G, van, Zyl-Smit R, et al. Diagnostic accuracy of a urine LAM strip-test for TB detection in HIV-infected hospitalised patients. Eur. Respir. J. 2012; 40: 1211-1220.
12. Theron G, Pooran A, Peter J, et al. Do adjunct TB tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting? Eur. Respir. J. 2011; 40: 161-168.
13. Perkins MD, Cunningham J,. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J. Infect. Dis. 2007; 196 (Suppl. 1): S15-27. (Pubitemid 47206081)
14. Steingart KR, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: A systematic review. Lancet Infect. Dis. 2006; 6: 664-674. (Pubitemid 44462695)
15. Cattamanchi A, Davis JL, Pai M, et al. Does bleach processing increase the accuracy of sputum smear microscopy for diagnosing pulmonary tuberculosis? J. Clin. Microbiol. 2010; 48: 2433-2439.
16. Srikanth P, Kamesh S, Daley P,. Bleach optimization of sputum smear microscopy for pulmonary tuberculosis. Indian J. Tuberc. 2009; 56: 174-184.
17. Marais BJ, Brittle W, Painczyk K, et al. Use of light-emitting diode fluorescence microscopy to detect acid-fast bacilli in sputum. Clin. Infect. Dis. 2008; 47: 203-207. (Pubitemid 351920621)
18. Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: A systematic review. Lancet Infect. Dis. 2006; 6: 570-581. (Pubitemid 44262344)
19. World Health Organization. Fluorescent Light-Emitting Diode (LED) Microscopy for Diagnosis of Tuberculosis Policy. WHO, Geneva, Switzerland, 2011.
20. Whitelaw A, Peter J, Sohn H, et al. Comparative cost and performance of light-emitting diode microscopy in HIV-tuberculosis-co-infected patients. Eur. Respir. J. 2011; 38: 1393-1397.
21. Keeler E, Perkins MD, Small P, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature 2006; 444 (Suppl. 1): 49-57.
22. Ramsay A, Yassin MA, Cambanis A, et al. Front-loading sputum microscopy services: an opportunity to optimise smear-based case detection of tuberculosis in high prevalence countries. J. Trop. Med. 2009; 2009: 398767.
23. Bonnet M, Ramsay A, Gagnidze L, et al. Reducing the number of sputum samples examined and thresholds for positivity: an opportunity to optimise smear microscopy. Int. J. Tuberc. Lung Dis. 2007; 11: 953-958. (Pubitemid 47425020)
24. Mase SR, Ramsay A, Ng V, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: A systematic review. Int. J. Tuberc. Lung Dis. 2007; 11: 485-495. (Pubitemid 46732633)
25. Albert H, Ademun PJ, Lukyamuzi G, et al. Feasibility of magnetic bead technology for concentration of mycobacteria in sputum prior to fluorescence microscopy. BMC Infect. Dis. 2011; 11: 125.
26. Applied Visual Sciences. Signature Mapping TBDx 2012.
27. Applied Visual Sciences. Signature mapping TBDx. 2012. [Accessed 28 June 2012.] Available from URL: http://www.appliedvs.com/technology.php?id=infectious
28. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375: 1920-1937.
29. Minion J, Leung E, Menzies D, et al. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: A systematic review and meta-analysis. Lancet Infect. Dis. 2010; 10: 688-698.
30. Coronel J, Roper M, Mitchell S, et al. MODS accreditation process for regional reference laboratories in Peru: validation by GenoType(R) MTBDRplus. Int. J. Tuberc. Lung Dis. 2010; 14: 1475-1480.
31. Farnia P, Masjedi MR, Mohammadi F, et al. Colorimetric detection of multidrug-resistant or extensively drug-resistant tuberculosis by use of malachite green indicator dye. J. Clin. Microbiol. 2008; 46: 796-799. (Pubitemid 351231341)
32. Gupta M, Singh NP, Kaur IR,. Evaluation of nitrate reductase assay for direct detection of drug resistance in Mycobacterium tuberculosis: rapid and inexpensive method for low-resource settings. Indian J. Med. Microbiol. 2010; 28: 363-365.
33. O'Grady J, Maeurer M, Mwaba P, et al. New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr. Opin. Pulm. Med. 2011; 17: 134-141.
34. Ling DI, Flores LL, Riley LW, et al. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS ONE 2008; 3: e1536.
35. Scott LE, McCarthy K, Gous N, et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: A prospective study. PLoS Med. 2011; 8: e1001061.
36. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 2010; 363: 1005-1015.
37. Davis JL, Huang L, Worodria W, et al. Nucleic acid amplification tests for diagnosis of smear-negative TB in a high HIV-prevalence setting: A prospective cohort study. PLoS ONE 2011; 6: e16321.
38. Barnard M, Albert H, Coetzee G, et al. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med. 2008; 177: 787-792. (Pubitemid 351490566)
39. Crudu V, Stratan E, Romancenco E, et al. First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. J. Clin. Microbiol. 2012; 50: 1264-1269.
40. Miotto P, Cabibbe AM, Mantegani P, et al. GenoType MTBDRsl performance on clinical samples with diverse genetic background. Eur. Respir. J. 2012; 40: 690-698.
41. Ling DI, Zwerling AA, Pai M,. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: A meta-analysis. Eur. Respir. J. 2008; 32: 1165-1174.
42. Chang K, Lu W, Wang J, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: A meta-analysis. J. Infect. 2012; 64: 580-588.
43. World Health Organization. Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resitance: Xpert MTB/RIF SYSTEM. WHO, Geneva, Switzerland, 2011. Publication number WHO/HTM/TB/2011.4.
44. World Health Organization. Rapid Implementation of the Xpert MTB/RIF Diagnostic Test. WHO, Geneva, Switzerland, 2011. Publication number WHO/HTM/TB/2011.2.
45. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J. Clin. Microbiol. 2010; 48: 229-237.
46. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: A multicentre implementation study. Lancet 2011; 377: 1495-1505.
47. Theron G, Peter J, van, Zyl-Smit R, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am. J. Respir. Crit. Care Med. 2011; 184: 132-140.
48. Lawn SD, Kerkhoff AD, Vogt M, et al. Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin. Infect. Dis. 2012; 54: 1071-1079.
49. Rachow A, Zumla A, Heinrich N, et al. Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay-a clinical validation study. PLoS ONE 2011; 6: e20458.
50. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: A prospective study. PLoS Med. 2011; 8: e1001067.
51. Xpert MTB/RIF [package insert]. Cepheid S, CA, 300-7810 Rev. A, April 2009.
52. Small PM, Pai M,. Tuberculosis diagnosis-time for a game change. N. Engl. J. Med. 2010; 363: 1070-1071.
53. Banada P, Sivasubramani SK, Blakemore R, et al. Containment of bioaerosol infection risk by the Xpert(R) MTB/RIF assay and its applicability to point-of-care settings. J. Clin. Microbiol. 2010; 48: 3551-3557.
54. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: A cost-effectiveness analysis. PLoS Med. 2011; 8: e1001120.
55. Theron G, Peter J, Dheda K,. Xpert MTB/RIF test for tuberculosis. Lancet 2011; 378: 481.
56. Schnippel K, Meyer-Rath G, Long L, et al. Scaling up Xpert MTB/RIF technology: the costs of laboratory-vs. clinic-based roll-out in South Africa. Trop. Med. Int. Health 2012; 17: 1142-1151.
57. Streicher EM, Müller B, Chihota V, et al. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. Infect. Genet. Evol. 2011; 12: 686-694.
58. Theron G, Pinto L, Peter J, et al. The use of an automated quantitative polymerase chain reaction (Xpert MTB/RIF) to predict the sputum smear status of tuberculosis patients. Clin. Infect. Dis. 2012; 54: 384-388.
59. Blakemore R, Nabeta P, Davidow AL, et al. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. Am. J. Respir. Crit. Care Med. 2011; 184: 1076-1084.
60. Pai NP, Vadnais C, Denkinger C, et al. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low-and middle-income countries. PLoS Med. 2012; 9: e1001306.
61. Trebucq A, Enarson DA, Chiang CY, et al. Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int. J. Tuberc. Lung Dis. 2011; 15: 1567-1572.
62. Flores LL, Steingart KR, Dendukuri N, et al. Systematic review and meta-analysis of antigen detection tests for the diagnosis of tuberculosis. Clin. Vaccine Immunol. 2011; 18: 1616-1627.
63. Dheda K, Davids V, Lenders L, et al. Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS ONE 2010; 5: e9848.
64. Minion J, Leung E, Talbot E, et al. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur. Respir. J. 2011; 38: 1398-1405.
65. Reither K, Saathoff E, Jung J, et al. Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis. BMC Infect. Dis. 2009; 9: 141.
66. Mutetwa R, Boehme C, Dimairo M, et al. Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients. Int. J. Tuberc. Lung Dis. 2009; 13: 1253-1259.
67. Shah M, Martinson NA, Chaisson RE, et al. Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis. J. Clin. Microbiol. 2010; 48: 2972-2974.
68. Lawn SD, Kerkhoff AD, Vogt M, et al. Clinical significance of lipoarabinomannan (LAM) detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis. AIDS 2012; 26: 1635-1643.
69. Peter JG, Cashmore TJ, Meldau R, et al. Diagnostic accuracy of induced sputum LAM ELISA for tuberculosis diagnosis in sputum-scarce patients. Int. J. Tuberc. Lung Dis. 2012; 16: 1108-1112.
70. Lawn SD, Kerkhoff AD, Vogt M, et al. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: A descriptive study. Lancet Infect. Dis. 2012; 12: 201-209.
71. Patel VB, Bhigjee AI, Paruk HF, et al. Utility of a novel lipoarabinomannan assay for the diagnosis of tuberculous meningitis in a resource-poor high-HIV prevalence setting. Cerebrospinal Fluid Res. 2009; 6: 13.
72. Dheda K, Van-Zyl Smit RN, Sechi LA, et al. Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting. PLoS ONE 2009; 4: e4689.
73. Arai H, Petchclai B, Khupulsup K, et al. Evaluation of a rapid immunochromatographic test for detection of antibodies to human immunodeficiency virus. J. Clin. Microbiol. 1999; 37: 367-370. (Pubitemid 29056406)
74. Grenier J, Pinto L, Nair D, et al. Widespread use of serological tests for tuberculosis: data from 22 high-burden countries. Eur. Respir. J. 2012; 39: 502-505.
75. WHO. Commercial Serodiagnostic Tests for Diagnosis of Tuberculosis. WHO, Geneva, 2011. [Accessed 30 October 2012.] Available from URL: http://whqlibdoc.who.int/publications/2011/9789241502054-eng.pdf
76. Ireton GC, Greenwald R, Liang H, et al. Identification of Mycobacterium tuberculosis antigens of high serodiagnostic value. Clin. Vaccine Immunol. 2010; 17: 1539-1547.
77. Zhang SL, Zhao JW, Sun ZQ, et al. Development and evaluation of a novel multiple-antigen ELISA for serodiagnosis of tuberculosis. Tuberculosis (Edinb) 2009; 89: 278-284.
78. Abebe F, Holm-Hansen C, Wiker HG, et al. Progress in serodiagnosis of Mycobacterium tuberculosis infection. Scand. J. Immunol. 2007; 66: 176-191. (Pubitemid 47063204)
79. Ivanyi J,. Serodiagnosis of tuberculosis: due to shift track. Tuberculosis (Edinb) 2012; 92: 31-37.
80. Kaushik A, Singh UB, Porwal C, et al. Diagnostic potential of 16 kDa (HspX, alpha-crystalline) antigen for serodiagnosis of tuberculosis. Indian J. Med. Res. 2012; 135: 771-777.
81. Xu JN, Chen JP, Chen DL,. Serodiagnosis efficacy and immunogenicity of the fusion protein of Mycobacterium tuberculosis composed of the 10-kilodalton culture filtrate protein, ESAT-6, and the extracellular domain fragment of PPE68. Clin. Vaccine Immunol. 2012; 19: 536-544.
82. Lee WG, Kim YG, Chung BG, et al. Nano/Microfluidics for diagnosis of infectious diseases in developing countries. Adv. Drug Deliv. Rev. 2010; 62: 449-457.
83. Wadhwa A, Hickling GJ, Eda S,. Opportunities for improved serodiagnosis of human tuberculosis, bovine tuberculosis, and paratuberculosis. Vet. Med. 2012; 2012: 674238.
84. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur. Respir. J. 2009; 33: 956-973.
85. Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999; 284: 1520-1523.
86. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-544. (Pubitemid 28319235)
87. Ling DI, Pai M, Davids V, et al. Are interferon-gamma release assays useful for diagnosing active tuberculosis in a high-burden setting? Eur. Respir. J. 2011; 38: 649-656.
88. Dheda K, Schwander SK, Zhu B, et al. The immunology of tuberculosis: from bench to bedside. Respirology 2010; 15: 433-450.
89. Diel R, Loddenkemper R, Nienhaus A,. Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: A meta-analysis. Chest 2012; 142: 63-75.
90. Haldar P, Thuraisingam H, Patel H, et al. Single-step QuantiFERON screening of adult contacts: A prospective cohort study of tuberculosis risk. Thorax 2012; Epub ahead of print.
91. Rubbo PA, Nagot N, Le Moing V, et al. Multicytokine detection improves latent tuberculosis diagnosis in health care workers. J. Clin. Microbiol. 2012; 50: 1711-1717.
92. Chegou NN, Black GF, Kidd M, et al. Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm. Med. 2009; 9: 21.
93. Kellar KL, Gehrke J, Weis SE, et al. Multiple cytokines are released when blood from patients with tuberculosis is stimulated with Mycobacterium tuberculosis antigens. PLoS ONE 2011; 6: e26545.
94. Frahm M, Goswami ND, Owzar K, et al. Discriminating between latent and active tuberculosis with multiple biomarker responses. Tuberculosis (Edinb) 2011; 91: 250-256.
95. Ruhwald M, Aabye MG, Ravn P,. IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions. Expert Rev. Mol. Diagn. 2012; 12: 175-187.
96. Aabye MG, Eugen-Olsen J, Werlinrud AM, et al. A simple method to quantitate IP-10 in dried blood and plasma spots. PLoS ONE 2012; 7: e39228.
97. Goletti D, Raja A, Syed Ahamed Kabeer B, et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific responses in HIV-infected persons? PLoS ONE 2010; 5: e12577.
98. Lange B, Vavra M, Kern W, et al. Sensitivity and specificity of a point-of-care test measuring IP-10 for the diagnosis of active tuberculosis. European Congress of Clinical Microbiology and Infectious Diseases, London, UK, 2012.
99. Bibova I, Linhartova I, Stanek O, et al. Detection of immune cell response to M. tuberculosis-specific antigens by quantitative polymerase chain reaction. Diagn. Microbiol. Infect. Dis. 2012; 72: 68-78.
100. Kasprowicz VO, Mitchell JE, Chetty S, et al. A molecular assay for sensitive detection of pathogen-specific T-cells. PLoS ONE 2011; 6: e20606.
101. Faley S, Seale K, Hughey J, et al. Microfluidic platform for real-time signaling analysis of multiple single T cells in parallel. Lab Chip 2008; 8: 1700-1712.
102. Liu Y, Kwa T, Revzin A,. Simultaneous detection of cell-secreted TNF-alpha and IFN-gamma using micropatterned aptamer-modified electrodes. Biomaterials 2012; 33: 7347-7355.
103. Boehme CC, Nabeta P, Henostroza G, et al. Operational feasibility of using loop-mediated isothermal amplification for diagnosis of pulmonary tuberculosis in microscopy centers of developing countries. J. Clin. Microbiol. 2007; 45: 1936-1940. (Pubitemid 46933929)
104. Blower S, Supervie V,. Predicting the future of XDR tuberculosis. Lancet Infect. Dis. 2007; 7: 443. (Pubitemid 46962341)
105. Liew M, Pryor R, Palais R, et al. Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin. Chem. 2004; 50: 1156-1164. (Pubitemid 38824225)
106. Ong DC, Yam WC, Siu GK, et al. Rapid detection of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis by high-resolution melting analysis. J. Clin. Microbiol. 2010; 48: 1047-1054.
107. Gabriel EM, Douarre PE, Fitzgibbon S, et al. High-resolution melting analysis for rapid detection of linezolid resistance (mediated by G2576T mutation) in Staphylococcus epidermidis. J. Microbiol. Methods 2012; 90: 134-136.
108. Ao W, Aldous S, Woodruff E, et al. Rapid detection of rpoB gene mutations conferring rifampin resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 2012; 50: 2433-2440.
109. Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 2007; 13: 380-387. (Pubitemid 46348124)
110. Zhang QD, March G, Noel V, et al. Label-free and reagentless electrochemical detection of PCR fragments using self-assembled quinone derivative monolayer: application to Mycobacterium tuberculosis. Biosens. Bioelectron. 2012; 32: 163-168.
111. Veigas B, Machado D, Perdigao J, et al. Au-nanoprobes for detection of SNPs associated with antibiotic resistance in Mycobacterium tuberculosis. Nanotechnology 2010; 21: 415101.
112. Augustynowicz-Kopec E, Zwolska Z,. [Tuberculosis caused by XDR resistant Mycobacterium tuberculosis in Poland. Microbiological and molecular analysis]. Pneumonol. Alergol. Pol. 2007; 75: 32-39.
113. Chin CD, Laksanasopin T, Cheung YK, et al. Microfluidics-based diagnostics of infectious diseases in the developing world. Nat. Med. 2011; 17: 1015-1019.
114. Schmidt R, Jacak J, Schirwitz C, et al. Single-molecule detection on a protein-array assay platform for the exposure of a tuberculosis antigen. J. Proteome Res. 2011; 10: 1316-1322.
115. Lumora. BART system. 2012. [Accessed 30 September 2012.] Available from URL: http://www.lumora.co.uk
116. Joubert MK, Kinsley N, Capovilla A, et al. A modeled structure of an aptamer-gp120 complex provides insight into the mechanism of HIV-1 neutralization. Biochemistry 2010; 49: 5880-5890.
117. Rotherham LS, Maserumule C, Dheda K, et al. Selection and application of ssDNA aptamers to detect TB infection using sputum samples. PLoS ONE. 2012; 7: e46862.
118. Chambers ST, Scott-Thomas A, Epton M,. Developments in novel breath tests for bacterial and fungal pulmonary infection. Curr. Opin. Pulm. Med. 2012; 18: 228-232.
119. Phillips M, Basa-Dalay V, Bothamley G, et al. Breath biomarkers of active pulmonary tuberculosis. Tuberculosis (Edinb) 2010; 90: 145-151.
120. Phillips M, Basa-Dalay V, Blais J, et al. Point-of-care breath test for biomarkers of active pulmonary tuberculosis. Tuberculosis (Edinb) 2012; 92: 314-320.
121. Wang F, Massire C, Li H, et al. Molecular characterization of drug-resistant Mycobacterium tuberculosis isolates circulating in China by multilocus pcr and electrospray ionization mass spectrometry. J. Clin. Microbiol. 2011; 49: 2719-2721.
122. Massire C, Ivy CA, Lovari R, et al. Simultaneous identification of mycobacterial isolates to the species level and determination of tuberculosis drug resistance by PCR followed by electrospray ionization mass spectrometry. J. Clin. Microbiol. 2011; 49: 908-917.
123. Xie H, Mire J, Kong Y, et al. Rapid point-of-care detection of the tuberculosis pathogen using a BlaC-specific fluorogenic probe. Nat. Chem. 2012; 4: 802-809.
124. Kong Y, Yao H, Ren H, et al. Imaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live mice. Proc. Natl Acad. Sci. U. S. A. 2010; 107: 12239-12244.
125. Jassal MS, Nedeltchev GG, Lee JH, et al. 13[C]-urea breath test as a novel point-of-care biomarker for tuberculosis treatment and diagnosis. PLoS ONE 2010; 5: e12451.
126. Maiga M, Abaza A, Bishai WR,. Current tuberculosis diagnostic tools & role of urease breath test. Indian J. Med. Res. 2012; 135: 731-736.
127. Dheda K, Zumla A, Onyebujoh P,. Research priorities in tuberculosis. In:, Zumla A, Schaaf S, (eds) A Treatise of Tuberculosis. Elsivier, London, 2008; 746-759.
128. Weyer K, Carai S, Nunn P,. Viewpoint TB diagnostics: what does the world really need? J. Infect. Dis. 2011; 204 (Suppl. 4): S1196-1202.